Comprehensive analysis of cell-extracellular matrix protein Ras suppressor-1 in function and prognosis of gastrointestinal cancers

Table 1 Correlation of Ras suppressor 1 expression and prognosis in gastric cancer with various clinicopathological factors

	OS (631)			FP (522)			PPS (384)
	n	HR	P value	n	HR	P value	n	HR	P value
Sex
Female	187	1.88 (1.22-2.89)	c	179	1.65 (1.09-2.51)	a	127	1.99 (1.21-3.25)	b
Male	349	1.36 (0.94-1.97)	0.098	341	1.4 (0.98-2.01)	0.064	256	1.52 (1.09-2.14)	a
Stage
I	62	2.84 (0.63-12.88)	0.16	60	2.7 (0.6-12.26)	0.18	31	2.79 (0.53-14.68)	0.21
II	135	1.47 (0.79-2.75)	0.22	131	0.73 (0.4-1.32)	0.29	105	2.01 (1.04-3.9)	a
III	197	1.27 (0.87-1.87)	0.22	186	1.51 (1.02-2.22)	a	142	1.2 (0.77-1.86)	0.42
IV	140	1.53 (0.95-2.46)	0.078	141	1.17 (0.74-1.84)	0.51	104	1.79 (1.13-2.83)	a
T
T2	241	1.64 (0.98-2.73)	0.055	239	1.42 (0.88-2.29)	0.15	196	1.57 (0.9-2.72)	0.11
T3	204	1.3 (0.92-1.83)	0.14	204	1.36 (0.95-1.94)	0.091	150	1.36 (0.93-1.99)	0.12
T4	38	3.33 (1.12-9.96)	a	39	2.12 (0.85-5.3)	0.1	29	4.68 (1.34-16.32)	b
N
N0	74	2.77 (1.19-6.43)	a	72	2.69 (1.16-6.23)	a	41	10.98 (2.7-44.62)	c
N1-3	422	1.54 (1.18-2.01)	b	423	1.35 (1.04-1.74)	a	337	1.64 (1.22-2.19)	c
M
M0	444	1.72 (1.2-2.47)	b	443	1.63 (1.16-2.31)	b	342	1.77 (1.31-2.4)	c
M1	56	1.84 (1.02-3.29)	a	56	1.44 (0.79-2.6)	0.23	56	2.09 (0.98-4.45)	0.052
HER2 status
Negative	429	1.46 (1.12-1.91)	b	429	1.55 (1.06-2.26)	a	283	1.79 (1.28-2.5)	c
Positive	202	1.41 (0.95-2.09)	0.086	166	1.46 (0.9-2.38)	0.13	101	1.46 (0.89-2.4)	0.14
Treatment
Surgery alone	380	1.44 (1.07-1.93)	a	375	1.36 (0.97-1.9)	0.071	277	1.82 (1.31-2.52)	c
5-FU-based adjuvant	34	1.77 (0.69-4.52)	0.23	34	1.8 (0.77-4.25)	0.17	21	0.39 (0.13-1.18)	0.085
Other adjuvant	76	2.65 (1.09-6.4)	a	80	3.46 (1.03-11.67)	a	74	2.5 (0.98-6.41)	a

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

5-FU: 5-fluorouracil; FS: First progression; HR: Hazard ratio; OS: Overall survival; PPS: Post-progression survival.